Mesothelin enhances ovarian cancer invasion by MMP-7 expression through the MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) and JNK (c-Jun N-terminal kinase) signal transduction pathways. Here, MSLN is linked to ovarian carcinoma.